Innovative science and solutions that expand access to valued treatments.
Transformative therapies for rare diseases with high unmet needs.
With the urgency patients require and the precision health systems demand.
December 30, 2019
Effective December 27, 2019, DSP has acquired from Roivant 100% of “Sumitovant Biopharma,” a newly formed company, and Roivant’s ownership interest in the five subsidiary companies, including Enzyvant, that comprise Sumitovant.
November 1, 2019
Under a definitive agreement signed yesterday, DSP will acquire Roivant’s ownership interest in Enzyvant and four other Roivant companies with promising pipelines.